Skip to main content

Table 3 Changes observed in the TMD subgroups during 3 months of occlusal split treatment

From: Changes in salivary oxidative status, salivary cortisol, and clinical symptoms in female patients with temporomandibular disorders during occlusal splint therapy: a 3-month follow up

 

Biomarkera

 

Diagnosis (source)

p +

(TIME)

Pain intensity

 

MP (n = 6*)

DD(n = 6*)

Low (n = 6**)

High (n = 6**)

INTERACTION

Mean

(95% CI)

Mean

(95% CI)

Mean

(95% CI)

Mean

(95% CI)

p+

(TIME)

p+

(TIME*SOURCE)

p+

(TIME*INTENSITY)

Morning

TAC

T0

0.62

0.25–0.99

0.50

0.13–0.87

0.074

0.40

0.19–0.61

0.72

0.31–1.13

0.076

0.48

0.91

T1

0.48

0.24–0.71

0.49

0.10–0.87

0.33

0.08–0.57

0.63

0.35–0.92

T2

0.37

0.04–0.70

0.34

−0.05-0.74

0.22

−0.02-0.48

0.48

0.09–0.48

MDA

T0

2.37

1.69–3.05

2.23

1.73–2.73

0.15

2.09

1.54–2.65

2.50

1.94–3.06

0.21

0.14

0.33

T1

1.57

0.88–2.25

2.07

1.33–2.82

1.75

1.13–2.37

1.89

1.01–2.78

T2

1.81

1.27–2.34

2.28

1.75–2.81

2.07

1.61–2.53

2.01

1.31–2.71

SOD

T0

3.42

2.92–3.91

3.60

3.28–3.93

0.51

3.43

2.99–3.87

3.58

3.17–4.01

0.53

0.63

0.78

T1

3.44

3.15–3.73

3.48

3.16–3.81

3.35

3.12–3.58

3.58

3.25–3.90

T2

3.40

3.03–3.77

3.39

3.07–3.71

3.31

3.10–3.52

3.48

3.06–3.91

UA

T0

2.74

2.37–3.11

2.60

2.22–2.98

0.17

2.53

2.37–2.69

2.81

2.34–3.27

0.19

0.35

0.98

T1

2.60

2.43–2.78

2.64

2.20–3.08

2.49

2.22–2.76

2.75

2.42–3.08

T2

2.50

1.96–3.03

2.49

1.92–3.07

2.35

1.97–2.73

2.64

2.01–3.29

SC

T0

1.17

1.06–1.29

0.82

0.66–0.98

0.50

1.02

0.78–1.26

0.97

0.72–1.23

0.49

0.10

0.73

T1

1.02

0.78–1.24

0.82

0.69–0.95

0.95

0.71–1.19

0.88

0.70–1.07

T2

1.05

0.84–1.26

1.00

0.66–1.33

0.99

0.72–1.26

1.06

0.77–1.34

Afternoon

TAC

T0

0.60

0.34–0.86

0.58

0.39–0.77

0.036*

0.48

0.38–0.57

0.71

0.46–0.95

0.045*

0.17

0.50

T1

0.50

0.26–0.74

0.47

0.10–0.84

0.43

0.22–0.63

0.54

0.17–0.92

T2

0.35

0.24–0.46

0.51

0.31–0.71

0.37

0.23–0.51

0.49

0.29–0.69

MDA

T0

2.76

2.39–3.13

2.55

1.81–3.30

0.52

2.47

1.87–3.07

2.84

2.31–3.36

0.38

0.43

0.02*

T1

2.34

1.58–3.10

2.69

1.87–3.51

2.86

2.18–3.54

2.17

1.42–2.92

T2

2.31

1.63–2.98

2.53

1.82–3.24

2.62

2.49–2.75

2.21

1.28–3.14

SOD

T0

3.31

2.85–3.76

3.52

3.28–3.77

0.23

3.40

3.01–3.80

3.43

3.06–3.80

0.22

0.88

0.78

T1

3.23

2.72–3.74

3.41

3.24–3.58

3.27

2.81–3.73

3.37

3.06–3.68

T2

3.29

3.03–3.55

3.54

3.38–3.71

3.41

3.13–3.68

3.43

3.18–3.67

UA

T0

2.69

2.31–3.07

2.70

2.52–2.88

0.39

2.56

2.34–2.78

2.83

2.55–3.11

0.30

0.76

0.03*

T1

2.68

2.37–2.99

2.74

2.51–2.97

2.69

2.45–2.92

2.73

2.43–3.04

T2

2.56

2.19–2.93

2.67

2.33–3.01

2.51

2.23–2.77

2.73

2.34–3.12

SC

T0

0.50

0.19–0.80

0.28

0.04–0.60

0.99

0.50

0.20–0.80

0.28

0.04–0.60

0.99

0.24

0.04*

T1

0.45

0.07–0.82

0.33

0.11–0.55

0.41

0.15–0.69

0.35

0.01–0.70

T2

1.57

0.17–0.98

0.21

0.05–0.38

0.30

0.08–0.53

0.48

0.03–0.93

  1. *pooled regardless of pain intensity; **pooled regardless of pathology source (diagnostic subgroup)
  2. TAC Total antioxidant capacity, MDA Malondialdehyde, SOD Superoxide dismutase, UA Uric acid, SC Salivary cortisol, CI Confidence interval, TMD Temporomandibular disorders, DD Disc displacement, MP Myofascial pain, T0 baseline, T1 1st month of treatment, T2 3rd month of treatment
  3. alog transformed data; +analysis of variance (ANOVA) for repeated measurements